EUCTR2009-011022-33-BE进行中（未招募）不适用
A phase II, double-blind study to evaluate the safety, reactogenicity and immunogenicity of two different formulations of GSK Biologicals’ pneumococcal protein candidate vaccine, when given as a booster dose in healthy young adults previously vaccinated in the primary vaccination study SPNG-001 (111651). - SPNG-006 BST:001
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who the investigator believes will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.
- •A male or female between, and including, 18 and 41 years old at the time of vaccination.
- •Subjects who previously participated in the study SPNG-001 (111651) and received either dPly/PhtD-10 or dPly/PhtD-30 vaccine formulation during the primary study.
- •Written informed consent obtained from the subject.
- •Free of obvious health problems as established by medical history, clinical examination and clinical laboratory assessment before entering into the study.
- •Female subjects of non-childbearing potential may be enrolled in the study.
- •- Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
- •Female subjects of childbearing potential may be enrolled in the study, if the subject:
- •- has practiced adequate contraception for 30 days prior to vaccination, and
- •- has a negative pregnancy test on the day of vaccination, and
- •- has agreed to continue adequate contraception during the entire treatment period and for 2 months after vaccination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the vaccination, or planned use during the study period.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination. (For corticosteroids, this will mean prednisone = 10 mg/day, or equivalent. Inhaled and topical steroids are allowed.)
- •Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting 30 days prior to the vaccination and ending one month (minimum 30 days) after vaccination.
- •Administration of any pneumococcal vaccine other than the study vaccine during the period between end of study SPNG-001 and study vaccination.
- •Bacterial pneumonia within the period between end of study SPNG-001 and study vaccination.
- •Invasive pneumococcal disease (IPD) within the period between end of study SPNG-001 and study vaccination.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection (no laboratory testing required).
- •History of thrombocytopenia or bleeding disorder.
- •Anaphylactic reaction following the previous administration of the vaccine or history of reactions or allergic disease likely to be exacerbated by any component of the vaccine.
- •Current serious neurologic or mental disorders.
- •Inflammatory processes such as known chronic active infections (e.g. Hepatitis B, C).
- •All past or current malignancies (excluding non-melanic skin cancer) and lymphoproliferative disorders.
- •Acute disease at the time of enrolment/vaccination.
- •Acute disease is defined as the presence of a moderate or severe illness with or without fever). All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection without fever.
- •Fever is defined as temperature = 37.5°C on oral setting.
- •Fever at the time of vaccination.
- •Fever is defined as temperature = 37.5°C on oral setting.
- •Physical examination positive for acrocyanosis, jaundice, splenomegaly.
- •Acute or chronic, clinically significant anaemia, pulmonary, cardiovascular, hematologic, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests, at the discretion of the investigator, such as:
- •- Type 2 diabetes
- •- Uncontrolled hypertension
- •- Current or history of coronary artery disease or cardiac insufficiency
- •- Current or history of rheumatoid arthritis or temporal arthritis
- •Administration of immunoglobulins and/or any blood products within the three months preceding vaccination or planned administration during the study period.
- •Pregnant or lactating female.
- •Female planning to become pregnant or planning to discontinue contraceptive precautions.
- •History of chronic alcohol consumption and/or drug abuse.
- •Other conditions that the principal investigator judges may interfere with study findings.
研究者
相似试验
进行中（未招募）
1 期
A randomized phase II pilot study to evaluate safety and efficacy of the addition of vismodegib to standard neoadjuvant chemotherapy in triple negative breast cancer patients.MedDRA version: 17.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006199Term: Breast cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancerEUCTR2014-001287-35-ESClínica Universidad de Navarra/Universidad de Navarra40
已完成
不适用
A prospective trial investigating the safety and efficacy of dose-escalated radiotherapy for men with prostate cancer following insertion of a gel spacer between the prostate and rectumProstate CancerACTRN12621000056897Epworth HealthCare71
进行中（未招募）
不适用
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s diseaseEUCTR2006-004111-22-GRovartis Pharma Services AG146
进行中（未招募）
不适用
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s diseaseCushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to produce excess cortisol, leading to the subsequent development of the clinical signs and symptoms of hypercortisolism. Cushing's disease is associated with severe morbidity and premature mortality and most commonly affects adults aged 20-50, primarily femalesMedDRA version: 8.1Level: LLTClassification code 10011651Term: Cushing's diseaseEUCTR2006-004111-22-DEovartis Pharma Services AG100
进行中（未招募）
不适用
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s diseaseMedDRA version: 8.1Level: LLTClassification code 10011651Term: Cushing's diseaseCushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to produce excess cortisol, leading to the subsequent development of the clinical signs and symptoms of hypercortisolism. Cushing's disease is associated with severe morbidity and premature mortality and most commonly affects adults aged 20-50, primarily femalesEUCTR2006-004111-22-DKovartis Pharma Services AG146